Recursion Pharmaceuticals , Inc. (NASDAQ:RXRX), currently trading at $4.32 and showing signs of being undervalued according to InvestingPro Fair Value metrics, has announced the filing of a prospectus ...
Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., ...
KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results